paclitaxel combined with platinum

Phase 3Small molecule

FFourth Affiliated Hospital of Guangxi Medical University

paclitaxel combined with platinum is one of 43 small molecule programs targeting Cervical Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical CancerActive, not recruiting

Cervical CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

380 competitors in Cervical Cancer

#DrugCompanyPhaseTrials

Emend IV

Merck & Co.

Phase 3

1 2

Hycamtin

MMeitheal

Phase 3

9 3

Navelbine

PPierre Fabre Medicament

Phase 3

3 4

Gemzar

Eli Lilly

Phase 3

1 5

Rescue

Merck & Co.

Phase 3

1 6

Platinum Based Chemotherapy

Roche

Phase 3

1 7

Vindesine

GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

Phase 3

1 8

HLX10

Shanghai Henlius Biotech

Phase 3

1 9

Mitomycin C

GGynecologic Oncology Group

Phase 3

1 10

Neoadjuvant Therapy

SSun Yat-sen University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Cervical Cancer

NCT05735145

Clinical

Trials by Indication[1]

Cervical Cancer1 trial

Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer

Recruiting·FFourth Affiliated Hospital of Guangxi Medical University·Phase 3·NCT05735145·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for paclitaxel combined with platinum. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — paclitaxel combined with platinum compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for paclitaxel combined with platinum. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fourth Affiliated Hospital of Guangxi Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFourth Affiliated Hospital of Guangxi Medical University

paclitaxel combined with platinum

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Cervical Cancer1 trial

References

Drug Info

Quick Facts

Related News